Stocksigma LogoStocksigma Logo

Aptus Pharma Delivers Strong H1 FY27 Growth with Expansion Roadmap

Aptus Pharma reported robust financial results for the half year ended 30th Sep'26, with revenue from operations surging nearly twofold YoY to ₹48.92

Aptus Pharma Delivers Strong H1 FY27 Growth with Expansion Roadmap

Aptus Pharma Ltd · Investor Presentation · 23 Oct 2026, 11:01 pm

Aptus Pharma Delivers Strong H1 FY27 Growth with Expansion Roadmap Aptus Pharma reported robust financial results for the half year ended 30th Sep'26, with revenue from operations surging nearly twofold YoY to ₹48.92 crore, compared to ₹14.38 crore in H1 FY26. EBITDA stood at ₹7.68 crore, while net profit reached ₹5.08 crore against ₹1.75 crore in the previous year period. Acute therapy contributed ~44% of sales, followed by chronic (~20%) and wellness/OTC (~20%). Strategically, the company plans 46% geographic coverage by Mar'27, 20% in-house manufacturing by Mar'28, and a pan-India footprint by Mar'29.

Original exchange filing (PDF)

More announcements from Aptus Pharma Ltd

All Aptus Pharma Ltd announcements